AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Megan A. Hatlen1,2, Lan Wang1, Stephen D. Nimer1,2()
1. Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; 2. Weill Cornell Medical College, New York, NY 10065, USA
The AML1-ETO fusion transcription factor is generated by the t(8;21) translocation, which is present in approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid leukemia (AML) patients. Both human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis in the absence of secondary events. In this review, we discuss the pathogenetic insights that have been gained from identifying the various events that can cooperate with AML1-ETO to induce AML in vivo. We also discuss potential therapeutic strategies for t(8;21) positive AML that involve targeting the fusion protein itself, the proteins that bind to it, or the genes that it regulates. Recently published studies suggest that a targeted therapy for t(8;21) positive AML is feasible and may be coming sometime soon.
Corresponding Author(s):
Nimer Stephen D.,Email:snimer@med.miami.edu
引用本文:
. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches[J]. Frontiers of Medicine, 2012, 6(3): 248-262.
Megan A. Hatlen, Lan Wang, Stephen D. Nimer. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med, 2012, 6(3): 248-262.
- Mice died during embryogenesis, 12.5-13.5 days post coitum- Mice showed hemorrhaging in the central nervous system- Fetal liver hematopoiesis was blocked
[24]
AML1-ETO knocked-in to the Cbfα2 locus
- Mice died during embryogenesis, 12.5-14.5 days post coitum- Mice showed hemorrhaging in the central nervous system- Fetal liver hematopoiesis was blocked
[25]
Mice expressing AML1-ETO cDNA under a tetracycline-responsive promoter were bred to mice containing the murine mammary tumor virus-tet controlled transcriptional activator (MMTV-tTA) construct
- Mice showed normal hematopoiesis- Bone marrow cells showed enhanced serial replating ability
[12]
Mice in which a chromosomal translocation between AML1 and ETO genes could be generated through Cre/loxP-mediated recombination were crossed to Nestin-Cre mice
- The translocation was not detectable by PCR in DNA isolated from bone marrow, muscle, and lung. Trace amounts of the translocation were found in DNA isolated from testes, spleen, and liver- No malignancies were detected in mice aged 5 months or younger
[11]
Mice expressing AML1-ETO cDNA under the human MRP8 promoter
- Mice showed normal hematopoiesis- Treatment of newborn hMRP8-AML1-ETO transgenic mice with N-ethyl-N-nitrosourea resulted in 55% developing AML
[14]
Mice with a conditional AML1-ETO knock-in allele (under the endogenous AML1 promoter) were crossed to Mx1-Cre mice.
- Mice showed normal hematopoiesis- Bone marrow cells showed enhanced serial replating ability- Treatment with N-ethyl-N-nitrosourea resulted in 31% developing granulocytic sarcoma/AML
[13]
Mice contained an AML1-ETO-IRES-eGFP construct under the Ly6A locus
- Mice developed a spontaneous myeloproliferative disorder with a penetrance of 52% at 1 year and 82% at 14 months.
[15]
Transplantation models
Mouse c-Kit+Sca-1+Lin- bone marrow cells were transduced with the MSCV-AML1-ETO-IRES-eGFP cDNA construct and transplanted into lethally irradiated congenic recipients
- Mice showed an increased number of myeloid progenitors and c-Kit+Sca-1+Lin- cells in the bone marrow compartment- No hematopoietic malignancies were detected
[32]
Mouse whole bone marrow or whole E14.5 fetal liver cells were transduced with the truncated AML1-ETO cDNA (Mig-A/Etr) construct and transplanted into lethally irradiated recipients. MF-1, BALB c, or C57 mice were used
- Mice developed acute myeloid leukemia- MF-1 mice transplanted with transduced MF-1 E14.5 fetal liver cells had a median survival time of 20 weeks post-transplantation- MF-1 eGFP+ splenocytes stained as Lin-, Sca-1-, c-Kit+, FcyRII/IIImed, and CD34-
[57]
MF-1 mouse whole E14.5 fetal liver cells were transduced with the AML1-ETO9a cDNA (Migr1-AE9a) construct and transplanted into lethally irradiated MF-1 recipients
- The majority of the mice developed acute myeloid leukemia 16 weeks post-transplantation- eGFP+ cells stained as Lin-, Sca-1-, c-Kit+, FcyRII/IIImed, and CD34-
[59]
C57BL/6 mouse whole E14.5 fetal liver cells were transduced with the AML1-ETO9a cDNA (Migr1-AE9a) construct and transplanted into lethally irradiated C57BL/6 recipients
- Mice developed acute myeloid leukemia and had a median survival time of 25 weeks post-transplantation- eGFP+ cells stained as Lin-, Sca-1-, c-Kit + , FcyRII/IIImed, and CD34-
[59]
Whole E14.5 fetal liver cells from MRP8-AE transgenic mice were transduced with the AML1-ETO9a cDNA (Migr1-AE9a) construct and transplanted into lethally irradiated C57BL/6 recipients
- The majority of the mice developed acute myeloid leukemia 5 weeks post-transplantation- The eGFP+ Lin-Sca-1-c-Kit+, as well as the eGFP+ Lin-Sca-1+ c-Kit+ cells, were FcyRII/IIIlo–hi and CD34+
[59]
Human CD34+ hematopoietic cells were transduced with the MigR1-AML1-ETO cDNA construct and transplanted into NOD/SCID mice
- AML1-ETO expressing CD34+ cells had an enhanced self-renewal and proliferative ability- Engraftment in NOD/SCID mice was limited and did not result in leukemogenesis
[111,112]
Human CD34+ hematopoietic cells were transduced with FMEV retrovirus containing the AML1-ETO cDNA construct and transplanted into NOD/SCID mice
- AML1-ETO expressing CD34+ cells had an enhanced self-renewal ability- Engraftment in NOD/SCID mice was achieved, but did not result in leukemogenesis
[113]
Tab.1
Fig.1
Inhibitor
Target
Target cell
Phenotype
Reference
ABT-737
Bcl-2 family members
AML1-ETO and N-RasG12D coexpressing CD34 + cells
- Decreased cell growth
[85]
ALLN and calpain inhibitor III
Calpains
Kasumi-1 cells
- Decreased viability- Decreased colony formation- Degraded endogenous AML1-ETO protein
[88]
TSA
Class I and II HDACs
Kasumi-1 cells
- Reduced the half-life of AML1-ETO protein- Induced apoptosis
[100]
DEP
Class I HDACs
Kasumi-1 cells t(8;21) AML patient bone marrow cells
- Reduced the half-life of AML1-ETO protein- Induced apoptosis- Released AML1-ETO from HSP90- Upregulated ANXA1
[102]
17-AAG
HSP-90
Kasumi-1 cells t(8;21) AML patient bone marrow cells
- Reduced the half-life of AML1-ETO protein
[102]
SAHA
Class I and II HDACs
Kasumi-1 cells
- Induced apoptosis- Upregulated ANXA1
[117]
Methyl-prednisolone
Corticosteroid targets
Kasumi-1 cells
- Reduced colony formation ability- Induced myeloid differentiation- Induced apoptosis- Synergized with ARA-C and daunorubicin
[89]
Methotrexate
Dihydrofolate reductase
Kasumi-1 cellsNOD/SCID transplanted with SKNO-1 cells
AML1-ETO transgenic Zebrafish embryosK562 cells transduced with AML1-ETO
- Restored GATA1 expression- Removed the block in erythroid differentiation
[91]
Eri-B
Unknown
AML1-ETO positive cell linest(8;21) AML patient bone marrow cellsC57 mice transplanted with cells expressing truncated AML1-ETONude mice inoculated with Kasumi-1
- Induced apoptosis- Increased median survival- Reduced tumor volume of nude mice
[93]
Triptolide
Unknown
AML1-ETO positive cell linest(8;21) AML patient bone marrow cells
- Inhibited growth and proliferation
[94]
Bortezomib
Proteosome inhibitor
AML1-ETO positive cell linest(8;21) AML patient bone marrow cellsC57 mice transplanted with cells expressing truncated AML1-ETO
- Induced apoptosis- Inhibited growth and proliferation- Increased median survival
[96]
Lys-CoA-Tatand C646
p300
AML1-ETO positive cell linest(8;21) AML patient bone marrow cellsLeukemic AML1-ETO9a positive mouse cells
- Inhibited growth and proliferation- Increased median survival of secondary transplant recipients
[107]
Tab.2
1
Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16(2): 109-112 pmid:4125056
2
Müller AMS, Duque J, Shizuru JA, Lübbert M. Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. Oncogene 2008; 27(44): 5759-5773 doi: 10.1038/onc.2008.196 pmid:18604246
3
Yamasaki H, Era T, Asou N, Sanada I, Matutes E, Yamaguchi K, Takatsuki K. High degree of myeloid differentiation and granulocytosis is associated with t(8;21) smoldering leukemia. Leukemia 1995; 9(7): 1147-1153 pmid:7630188
4
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103(4): 620-625 pmid:3862359
5
Gao J, Erickson P, Gardiner K, Le Beau MM, Diaz MO, Patterson D, Rowley JD, Drabkin HA. Isolation of a yeast artificial chromosome spanning the 8;21 translocation breakpoint t(8;21)(q22;q22.3) in acute myelogenous leukemia. Proc Natl Acad Sci USA 1991; 88(11): 4882-4886 doi: 10.1073/pnas.88.11.4882 pmid:2052570
6
Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci USA 1991; 88(23): 10431-10434 doi: 10.1073/pnas.88.23.10431 pmid:1720541
7
Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80(7): 1825-1831 pmid:1391946
8
Erickson PF, Robinson M, Owens G, Drabkin HA. The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor. Cancer Res 1994; 54(7): 1782-1786 pmid:8137293
9
Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet 1992; 63(2): 81-88 doi: 10.1016/0165-4608(92)90384-K pmid:1423235
10
Shimizu K, Miyoshi H, Kozu T, Nagata J, Enomoto K, Maseki N, Kaneko Y, Ohki M. Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation. Cancer Res 1992; 52(24): 6945-6948 pmid:1458484
11
Buchholz F, Refaeli Y, Trumpp A, Bishop JM. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 2000; 1(2): 133-139 doi: 10.1093/embo-reports/kvd027 pmid:11265752
12
Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ, Little MT, Tenen DG, Zhang DE. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000; 96(6): 2108-2115 pmid:10979955
13
Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1(1): 63-74 doi: 10.1016/S1535-6108(02)00016-8 pmid:12086889
14
Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98(18): 10398-10403 doi: 10.1073/pnas.171321298 pmid:11526243
15
Fenske TS, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci USA 2004; 101(42): 15184-15189 doi: 10.1073/pnas.0400751101 pmid:15477599
16
Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84(2): 321-330 doi: 10.1016/S0092-8674(00)80986-1 pmid:8565077
17
Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93(8): 3444-3449 doi: 10.1073/pnas.93.8.3444 pmid:8622955
18
Calabi F, Pannell R, Pavloska G. Gene targeting reveals a crucial role for MTG8 in the gut. Mol Cell Biol 2001; 21(16): 5658-5666 doi: 10.1128/MCB.21.16.5658-5666.2001 pmid:11463846
19
Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 1998; 95(18): 10860-10865 doi: 10.1073/pnas.95.18.10860 pmid:9724795
20
Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 1998; 18(12): 7176-7184 pmid:9819404
21
Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18(12): 7185-7191 pmid:9819405
22
Frank R, Zhang J, Uchida H, Meyers S, Hiebert SW, Nimer SD. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B. Oncogene 1995; 11(12): 2667-2674 pmid:8545124
23
Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol 1995; 15(4): 1974-1982 pmid:7891692
24
Yergeau DA, Hetherington CJ, Wang Q, Zhang P, Sharpe AH, Binder M, Marín-Padilla M, Tenen DG, Speck NA, Zhang DE. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15(3): 303-306 doi: 10.1038/ng0397-303 pmid:9054947
25
Okuda T, Cai Z, Yang S, Lenny N, Lyu CJ, van Deursen JM, Harada H, Downing JR. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998; 91(9): 3134-3143 pmid:9558367
26
Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science 1995; 269(5229): 1427-1429 doi: 7660125" target="_blank">10.1126/science. pmid:7660125 pmid:7660125
27
Frei JV, Lawley PD. Thymomas induced by simple alkylating agents in C57BL/Cbi mice: kinetics of the dose response. J Natl Cancer Inst 1980; 64(4): 845-856 pmid:6928996
28
Wiemels JL, Xiao Z, Buffler PA, Maia AT, Ma X, Dicks BM, Smith MT, Zhang L, Feusner J, Wiencke J, Pritchard-Jones K, Kempski H, Greaves M. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99(10): 3801-3805 doi: 10.1182/blood.V99.10.3801 pmid:11986239
29
Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456(7218): 66-72 doi: 10.1038/nature07485 pmid:18987736
30
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361(11): 1058-1066 doi: 10.1056/NEJMoa0903840 pmid:19657110
31
Peterson LF, Boyapati A, Ahn EY, Biggs JR, Okumura AJ, Lo MC, Yan M, Zhang DE. Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts. Blood 2007; 110(3): 799-805 doi: 10.1182/blood-2006-11-019265 pmid:17412887
32
de Guzman CG, Warren AJ, Zhang Z, Gartland L, Erickson P, Drabkin H, Hiebert SW, Klug CA. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002; 22(15): 5506-5517 doi: 10.1128/MCB.22.15.5506-5517.2002 pmid:12101243
33
Grisolano JL, O’Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2003; 100(16): 9506-9511 doi: 10.1073/pnas.1531730100 pmid:12881486
34
Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, Spiekermann K, Humphries RK, Schnittger S, Kern W, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115(8): 2159-2168 doi: 10.1172/JCI24225 pmid:16025155
35
Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, Chen SJ. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108(6): 2450-2455 doi: 10.1073/pnas.1019625108 pmid:21262832
Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14(1): 49-64 doi: 10.1053/beha.2000.0115 pmid:11355923
38
Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002; 39(4 Suppl 3): 6-11 doi: 10.1053/shem.2002.36921 pmid:12447846
39
Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23(7): 1343-1345 doi: 10.1038/leu.2009.59 pmid:19295549
40
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O’Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363(25): 2424-2433 doi: 10.1056/NEJMoa1005143 pmid:21067377
41
Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adéla?de J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 2010; 24(2): 469-473 doi: 10.1038/leu.2009.218 pmid:19865112
42
Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, Calasanz MJ, Larrayoz MJ, Garcia-Delgado M, Giagounidis A, Malcovati L, Della Porta MG, J?dersten M, Killick S, Hellstr?m-Lindberg E, Cazzola M, Wainscoat JS. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010; 24(5): 1062-1065 doi: 10.1038/leu.2010.20 pmid:20182461
43
Menssen HD, Renkl HJ, Rodeck U, Maurer J, Notter M, Schwartz S, Reinhardt R, Thiel E. Presence of Wilms’ tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9(6): 1060-1067 pmid:7596170
44
Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Tamaki H, Oji Y, Kim EH, Soma T, Tatekawa T, Kawakami M, Kishimoto T, Sugiyama H. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23(5): 499-505 doi: 10.1016/S0145-2126(99)00037-5 pmid:10374864
45
Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006; 107(8): 3303-3312 doi: 10.1182/blood-2005-04-1656 pmid:16380455
46
Schwieger M, L?hler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 2002; 196(9): 1227-1240 doi: 10.1084/jem.20020824 pmid:12417632
47
Tallman MS, Hakimian D, Shaw JM, Lissner GS, Russell EJ, Variakojis D. Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993; 11(4): 690-697 pmid:8478662
48
Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 2007; 109(10): 4392-4398 doi: 10.1182/blood-2006-03-012575 pmid:17284535
49
Shiohara M, Koike K, Komiyama A, Koeffler HP. p21WAF1 mutations and human malignancies. Leuk Lymphoma 1997; 26(1-2): 35-41 pmid:9250785
50
Hayette S, Thomas X, Bertrand Y, Tigaud I, Callanan M, Thiebaut A, Charrin C, Archimbaud E, Magaud JP, Rimokh R. Molecular analysis of cyclin-dependent kinase inhibitors in human leukemias. Leukemia 1997; 11(10): 1696-1699 doi: 10.1038/sj.leu.2400814 pmid:9324291
51
Chim CS, Wong AS, Kwong YL. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. Am J Hematol 2005; 80(4): 282-287 doi: 10.1002/ajh.20503 pmid:16315255
52
Brakensiek K, L?nger F, Kreipe H, Lehmann U. Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML. Leuk Res 2005; 29(11): 1357-1360 doi: 10.1016/j.leukres.2005.04.012 pmid:15936816
53
Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 2008; 93(11): 1728-1733 doi: 10.3324/haematol.13044 pmid:18790797
54
Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369(6481): 574-578 doi: 10.1038/369574a0 pmid:7911228
55
Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371(6497): 534-537 doi: 10.1038/371534a0 pmid:7935768
56
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997; 277(5334): 1996-2000 doi: 10.1126/science.277.5334.1996 pmid:9302295
57
Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 2004; 101(49): 17186-17191 doi: 10.1073/pnas.0406702101 pmid:15569932
58
Wolford JK, Prochazka M. Structure and expression of the human MTG8/ETO gene. Gene 1998; 212(1): 103-109 doi: 10.1016/S0378-1119(98)00141-3 pmid:9661669
59
Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y, Chen IM, Chen Z, Rowley JD, Willman CL, Zhang DE. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12(8): 945-949 doi: 10.1038/nm1443 pmid:16892037
60
Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B, Shi JY, Wang YY, Wang JH, Chen Y, Li JM, Gu LJ, Tang JY, Shen ZX, Gu BW, Zhao WL, Chen Z, Chen SJ. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009; 23(9): 1598-1604 doi: 10.1038/leu.2009.104 pmid:19458628
61
Fey MF, Greil R, Jost LM;ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol 2005; 16(Suppl 1): i48-i49 doi: 10.1093/annonc/mdi802 pmid:15888751
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD ; Cancer and Leukemia Group B (CALGB 8461).Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100(13): 4325-4336 doi: 10.1182/blood-2002-03-0772 pmid:12393746
Ambros V. The functions of animal microRNAs. Nature 2004; 431(7006): 350-355 doi: 10.1038/nature02871 pmid:15372042
66
Zhang B, Wang Q, Pan X. MicroRNAs and their regulatory roles in animals and plants. J Cell Physiol 2007; 210(2): 279-289 doi: 10.1002/jcp.20869 pmid:17096367
67
Havelange V, Garzon R. MicroRNAs: emerging key regulators of hematopoiesis. Am J Hematol 2010; 85(12): 935-942 doi: 10.1002/ajh.21863 pmid:20941782
68
Fazi F, Racanicchi S, Zardo G, Starnes LM, Mancini M, Travaglini L, Diverio D, Ammatuna E, Cimino G, Lo-Coco F, Grignani F, Nervi C. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 2007; 12(5): 457-466 doi: 10.1016/j.ccr.2007.09.020 pmid:17996649
69
Brioschi M, Fischer J, Cairoli R, Rossetti S, Pezzetti L, Nichelatti M, Turrini M, Corlazzoli F, Scarpati B, Morra E, Sacchi N, Beghini A. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits. Neoplasia 2010; 12(11): 866-876 pmid:21076613
70
Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005; 123(5): 819-831 doi: 10.1016/j.cell.2005.09.023 pmid:16325577
71
Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, Liuzzi F, Lulli V, Morsilli O, Santoro S, Valtieri M, Calin GA, Liu CG, Sorrentino A, Croce CM, Peschle C. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102(50): 18081-18086 doi: 10.1073/pnas.0506216102 pmid:16330772
72
Zaidi SK, Dowdy CR, van Wijnen AJ, Lian JB, Raza A, Stein JL, Croce CM, Stein GS. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network. Cancer Res 2009; 69(21): 8249-8255 doi: 10.1158/0008-5472.CAN-09-1567 pmid:19826043
73
Tanoue T, Yamamoto T, Maeda R, Nishida E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 alpha and beta MAPKs. J Biol Chem 2001; 276(28): 26629-26639 doi: 10.1074/jbc.M101981200 pmid:11359773
74
Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, Qian Z, Neilly MB, Jin J, Zhang Y, Bohlander SK, Zhang DE, Larson RA, Le Beau MM, Thirman MJ, Golub TR, Rowley JD, Chen J. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105(40): 15535-15540 doi: 10.1073/pnas.0808266105 pmid:18832181
75
Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, L?wenberg B, Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350(16): 1617-1628 doi: 10.1056/NEJMoa040465 pmid:15084694
76
Bullinger L, D?hner K, Bair E, Fr?hling S, Schlenk RF, Tibshirani R, D?hner H, Pollack JR. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350(16): 1605-1616 doi: 10.1056/NEJMoa031046 pmid:15084693
77
Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, K?hler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H. Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol 2004; 24(7): 2890-2904 doi: 10.1128/MCB.24.7.2890-2904.2004 pmid:15024077
78
Steffen B, Knop M, Bergholz U, Vakhrusheva O, Rode M, K?hler G, Henrichs MP, Bulk E, Hehn S, Stehling M, Dugas M, B?umer N, Tschanter P, Brandts C, Koschmieder S, Berdel WE, Serve H, Stocking C, Müller-Tidow C. AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. Blood 2011; 117(16): 4328-4337 doi: 10.1182/blood-2009-09-242545 pmid:21245488
79
Balkhi MY, Trivedi AK, Geletu M, Christopeit M, Bohlander SK, Behre HM, Behre G. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 2006; 25(53): 7041-7058 doi: 10.1038/sj.onc.1209689 pmid:16732326
80
Balkhi MY, Christopeit M, Chen Y, Geletu M, Behre G. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp Hematol 2008; 36(11): 1449-1460.e1 doi: 10.1016/j.exphem.2008.05.008 pmid:18687517
81
Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP. Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 2000; 60(7): 1815-1817 pmid:10766164
82
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8(6): 1731-1739 pmid:12060610
83
Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107(10): 3847-3853 doi: 10.1182/blood-2005-08-3522 pmid:16434492
84
Kuchenbauer F, Schnittger S, Look T, Gilliland G, Tenen D, Haferlach T, Hiddemann W, Buske C, Schoch C. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134(6): 616-619 doi: 10.1111/j.1365-2141.2006.06229.x pmid:16938118
85
Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood 2011; 117(7): 2237-2240 doi: 10.1182/blood-2010-01-264119 pmid:21200020
86
Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 1996; 93(24): 14059-14064 doi: 10.1073/pnas.93.24.14059 pmid:8943060
87
Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human pre-leukemia induced by AML1-ETO. Blood 2012Feb14. [Epub ahead of print] doi: 10.1182/blood-2012-01-403212 doi: 10.1182/blood-2012-01-403212 pmid:22337712
88
Osman D, Gobert V, Ponthan F, Heidenreich O, Haenlin M, Waltzer L. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. Proc Natl Acad Sci USA 2009; 106(29): 12043-12048 doi: 10.1073/pnas.0902449106 pmid:19581587
89
Corsello SM, Roti G, Ross KN, Chow KT, Galinsky I, DeAngelo DJ, Stone RM, Kung AL, Golub TR, Stegmaier K. Identification of AML1-ETO modulators by chemical genomics. Blood 2009; 113(24): 6193-6205 doi: 10.1182/blood-2008-07-166090 pmid:19377049
90
Shimohakamada Y, Shinohara K, Fukuda N. Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol 2001; 74(2): 173-177 doi: 10.1007/BF02982001 pmid:11594518
91
Yeh JR, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat Chem Biol 2009; 5(4): 236-243 doi: 10.1038/nchembio.147 pmid:19172146
92
Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007; 109(8): 3441-3450 doi: 10.1182/blood-2006-06-032250 pmid:17197433
93
Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB, Weng ZY, Wu WL, Weng XQ, Sun XJ, Chen Z, Sun HD, Chen SJ. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 2007; 14(2): 306-317 doi: 10.1038/sj.cdd.4401996 pmid:16778832
94
Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, Hu AM, Xu L, Zhou GB. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res 2011; 35(2): 214-218 doi: 10.1016/j.leukres.2010.07.013 pmid:20691473
95
Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX, Jin XL, You JH, Yang G, Shen ZX, Chen J, Xiong SM, Chen GQ, Xu F, Liu YW, Chen Z, Chen SJ. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102(4): 1104-1109 doi: 10.1073/pnas.0408831102 pmid:15650049
96
Fang HT, Zhang B, Pan XF, Gao L, Zhen T, Zhao HX, Ma L, Xie J, Liu Z, Yu XJ, Cheng X, Feng TT, Zhang FX, Yang Y, Hu ZG, Sheng GQ, Chen YL, Chen SJ, Chen Z, Zhou GB. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci USA 2012; 109(7): 2521-2526 doi: 10.1073/pnas.1121341109 pmid:22308476
97
Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111(4): 2364-2373 doi: 10.1182/blood-2007-08-110171 pmid:18083845
98
Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia 2012Jan13. [Epub ahead of print] doi: 10.1038/leu.2011.376 doi: 10.1038/leu.2011.376 pmid:22289984
99
Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298 doi: 10.1007/978-1-4020-6554-5_13 pmid:18437899
101
Klisovic MI, Maghraby EA, Parthun MR, Guimond M, Sklenar AR, Whitman SP, Chan KK, Murphy T, Anon J, Archer KJ, Rush LJ, Plass C, Grever MR, Byrd JC, Marcucci G. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 2003; 17(2): 350-358 doi: 10.1038/sj.leu.2402776 pmid:12592335
102
Yang G, Thompson MA, Brandt SJ, Hiebert SW. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Oncogene 2007; 26(1): 91-101 doi: 10.1038/sj.onc.1209760 pmid:16799637
103
Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003; 2(10): 971-984 pmid:14578462
104
Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94(7): 504-513 doi: 10.1093/jnci/94.7.504 pmid:11929951
105
Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J 1998; 17(11): 2994-3004 doi: 10.1093/emboj/17.11.2994 pmid:9606182
106
Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M, Yamamoto G, Nitta E, Yamagata T, Sasaki K, Mitani K, Ogawa S, Chiba S, Hirai H. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 2004; 279(15): 15630-15638 doi: 10.1074/jbc.M400355200 pmid:14752096
107
Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011; 333(6043): 765-769 doi: 10.1126/science.1201662 pmid:21764752
108
Zheng Y, Balasubramanyam K, Cebrat M, Buck D, Guidez F, Zelent A, Alani RM, Cole PA. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J Am Chem Soc 2005; 127(49): 17182-17183 doi: 10.1021/ja0558544 pmid:16332055
109
Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, Larocca C, Saldanha SA, Abagyan R, Sun Y, Meyers DJ, Marmorstein R, Mahadevan LC, Alani RM, Cole PA. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 2010; 17(5): 471-482 doi: 10.1016/j.chembiol.2010.03.006 pmid:20534345
110
Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells Mol Dis 2009; 43(1): 30-34 doi: 10.1016/j.bcmd.2009.03.005 pmid:19386523
111
Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99(1): 15-23 doi: 10.1182/blood.V99.1.15 pmid:11756147
112
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003; 102(13): 4369-4376 doi: 10.1182/blood-2003-05-1762 pmid:12946995
113
B?secke J, Schwieger M, Griesinger F, Schiedlmeier B, Wulf G, Trümper L, Stocking C. AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. Leuk Lymphoma 2005; 46(2): 265-272 doi: 10.1080/10428190400010767 pmid:15621811
114
Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001; 20(40): 5660-5679 doi: 10.1038/sj.onc.1204593 pmid:11607817
115
Nimer SD, Moore MA. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 2004; 23(24): 4249-4254 doi: 10.1038/sj.onc.1207673 pmid:15156180
116
Peterson LF, Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene 2004; 23(24): 4255-4262 doi: 10.1038/sj.onc.1207727 pmid:15156181
117
Tabe Y, Jin L, Contractor R, Gold D, Ruvolo P, Radke S, Xu Y, Tsutusmi-Ishii Y, Miyake K, Miyake N, Kondo S, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ 2007; 14(8): 1443-1456 doi: 10.1038/sj.cdd.4402139 pmid:17464329